

RESEARCH

Open Access

SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin

Gagan Deep^{1,2*}, Anil K Jain¹, Anand Ramteke^{1,3}, Harold Ting¹, Kavitha C Vijendra¹, Subhash C Gangar¹, Chapla Agarwal^{1,2} and Rajesh Agarwal^{1,2*}

Abstract

Background: A better molecular understanding of prostate carcinogenesis is warranted to devise novel targeted preventive and therapeutic strategies against prostate cancer (PCA), a major cause of mortality among men. Here, we examined the role of two epithelial-to-mesenchymal transition (EMT) regulators, the adherens junction protein E-cadherin and its transcriptional repressor SNAI1, in regulating the aggressiveness of PCA cells.

Methods: The growth rate of human prostate carcinoma PC3 cells with stable knock-down of E-cadherin (ShEC-PC3) and respective control cells (Sh-PC3) was compared in MTT and clonogenic assays in cell culture and in nude mouse xenograft model *in vivo*. Stemness of ShEC-PC3 and Sh-PC3 cells was analyzed in prostasphere assay. Western blotting and immunohistochemistry (IHC) were used to study protein expression changes following E-cadherin and SNAI1 knock-down. Small interfering RNA (siRNA) technique was employed to knock-down SNAI1 protein expression in ShEC-PC3 cells.

Results: ShEC-PC3 cells exerted higher proliferation rate both in cell culture and in athymic nude mice compared to Sh-PC3 cells. ShEC-PC3 cells also formed larger and a significantly higher number of prostaspheres suggesting an increase in the stem cell-like population with E-cadherin knock-down. Also, ShEC-PC3 prostaspheres disintegration, in the presence of serum and attachment, generated a bigger mass of proliferating cells as compared to Sh-PC3 prostaspheres. Immunoblotting/IHC analyses showed that E-cadherin knock-down increases the expression of regulators/biomarkers for stemness (CD44, cleaved Notch1 and Egr-1) and EMT (Vimentin, pSrc-tyr416, Integrin β 3, β -catenin, and NF- κ B) in cell culture and xenograft tissues. The expression of several bone metastasis related molecules namely CXCR4, uPA, RANKL and RunX2 was also increased in ShEC-PC3 cells. Importantly, we observed a remarkable increase in SNAI1 expression in cytoplasmic and nuclear fractions, prostaspheres and xenograft tissues of ShEC-PC3 cells. Furthermore, SNAI1 knock-down by specific siRNA strongly inhibited the prostasphere formation, clonogenicity and invasiveness, and decreased the level of pSrc-tyr416, total Src and CD44 in ShEC-PC3 cells. Characterization of RWPE-1, WPE1-NA22, WPE1-NB14 and DU-145 cells further confirmed that low E-cadherin is associated with higher SNAI1 expression and prostasphere formation.

Conclusions: Together, these results suggest that E-cadherin loss promotes SNAI1 expression that controls the aggressiveness of PCA cells.

Keywords: Prostate cancer, E-cadherin, SNAI1, Stemness, EMT

* Correspondence: Gagan.deep@ucdenver.edu; Rajesh.agarwal@ucdenver.edu

¹Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, USA

²University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado, USA

Full list of author information is available at the end of the article

Background

Prostate cancer (PCA) is the most common non-cutaneous cancer, and is the second leading cause of cancer-related deaths in American men. According to the American Cancer Society, in 2013, there will be an estimated 238,590 new cases and 29,720 deaths from PCA in the United States [1]. Patients with localized PCA have a high 5-year survival rate and a relatively low mortality to incidence ratio compared to other cancer types [2]. However, in patients with clinically detectable metastasis, the median survival is reduced to only 12–15 months; therefore, metastasis is the main cause of high mortality among PCA patients [2–4]. PCA cells metastasize to several organs; however, bone is the most frequent site for metastasis [3,5]. Patients with bone metastasis suffer extreme bone pain, spinal-cord compression and fractures [6–8]. In addition, replacement of bone marrow by growing PCA cells disrupts normal haematopoiesis, causing anemia and enhanced susceptibility to infections [7]. Therefore, a better understanding of the early events associated with PCA metastasis is warranted to lower mortality and improve patient's quality of life.

Now it is known that PCA metastasis involves multiple steps including the acquisition of invasiveness through 'EMT' (epithelial to mesenchymal transition), access to systemic blood or lymphatic systems (intravasation), survival in the circulation, arrest in the microvasculature and subsequent extravasation, and growth at distant organs [9]. Among these events, EMT has often been described as absolutely necessary and indispensable for metastasis [9,10]. During EMT, cancer cells shed their epithelial features, detach from epithelial sheets and undergo cytoskeletal changes towards a 'mesenchymal phenotype' and acquire a high degree of motility and invasiveness [10,11]. Recent studies have suggested that EMT not only enhances invasiveness and migratory potential but also confers several aggressive attributes to cancer cells such as enhanced stemness, drug and anoikis resistance, etc. [12–14]; and that these features could provide a survival advantage to cancer cells during the arduous metastasis journey from primary organs to distant metastatic sites. Therefore, understanding and targeting the role of EMT regulators in conferring an aggressive phenotype to PCA cells could be useful in effectively inhibiting metastatic progression.

The molecular regulation of EMT is extremely complex and involves numerous interconnected as well as independent pathways and signaling molecules [10,11,15]. However, several of these pathways converge together to down-regulate the expression of adherens junction molecule E-cadherin [16]. E-cadherin is a transmembrane glycoprotein that regulates cell-cell adhesion, cell polarity and shape through its interactions with E-cadherin molecules on adjacent cells as well as with the actin microfilament network via catenins (α , β and p120) [16]. The loss of


E-cadherin frees catenins from the membranous pool, thus making them available for nuclear signaling, which then promote cancer cell proliferation, invasiveness and EMT [10,17]. E-cadherin expression is regulated through a combination of genetic, epigenetic, transcriptional and post-transcriptional mechanisms [10,16]. Major transcriptional repressors of E-cadherin are zinc finger family members SNAI1 (SNAIL1 in drosophila) and Slug, the basic helix-loop-helix factors E47 and Twist, and two-handed zinc factors ZEB1 and SIP1 [10]. Importantly, the loss of E-cadherin function has been implicated in the progression and metastasis of several malignancies including PCA [18,19]. Furthermore, reduced E-cadherin expression has been correlated with higher tumor grade and poor prognosis in PCA patients [20–23]. However, the molecular changes associated with E-cadherin loss that are responsible for PCA aggressiveness are still not clear. Results from the present study suggest that E-cadherin loss could enhance proliferation and stemness in PCA cells through altering the expression of several signaling molecules but mainly through its transcriptional repressor SNAI1.

SNAI1 is one of the master EMT regulators and is a promoter of metastasis, that represses the expression of several epithelial markers (E-cadherin, claudin, occludin, etc.) and enforces a mesenchymal phenotype by promoting the expression of mesenchymal genes (fibronectin, vimentin, α -SMA etc.) [10,24,25]. SNAI1 is overexpressed in several cancer cells including PCA where it is suggested to be upregulated at early stages of PCA development [26]. High SNAI1 expression in tumors often correlates with disease aggressiveness and poor prognosis [23,27,28]. SNAI1 has been implicated in cancer cell survival, cell cycle regulation, apoptosis evasion, cell adhesion, neuroendocrine differentiation, and chemoresistance [24,25]. In the present study, we analyzed the role of SNAI1 in the aggressiveness of PCA cells with low E-cadherin expression (via Stable E-cadherin knock-down). Our results for the first time showed that SNAI1 could control the clonogenicity, stemness and invasiveness of PCA cells with low E-cadherin expression.

Results

E-cadherin knock-down increases proliferation of human PCA PC3 cells

First we analyzed the effect of E-cadherin loss on the proliferation of PC3 cells where ShEC-PC3 cells with E-cadherin knock-down showed higher proliferation at 24, 48, and 72 hrs after seeding compared to vector control Sh-PC3 cells (Figure 1A). MTT assay results were further confirmed in a clonogenic assay which showed that E-cadherin knockdown significantly ($p \leq 0.001$) enhanced the clonogenicity of PC3 cells (Figure 1B). Next, ShEC-PC3 and Sh-PC3 cells were subcutaneously injected in athymic male nude mice to compare their *in vivo* growth rate. As




shown in Figure 1C, both Sh-PC3 and ShEC-PC3 cells formed xenografts, however, the tumor volume was consistently higher in ShEC-PC3 cells compared to Sh-PC3 cells. At the end of the study, xenograft tissues were analyzed for proliferation biomarkers (PCNA and Ki-67) by IHC. ShEC-PC3 tumors showed a higher expression of both PCNA and Ki-67 positive cells (Figure 1D), suggesting an increased proliferation rate *in vivo*. Taken together, these results suggested that E-cadherin knock-down increases the proliferation rate of PC3 cells both *in vitro* and *in vivo*.

E-cadherin knock-down enhances the stemness of human PCA PC3 cells

Next we examined the effect of E-cadherin knock-down on the stemness of PCA cells in a prostatesphere assay. The prostatesphere assay is considered the ‘gold standard’

to determine the self-renewal capability of a stem-like cell population (CSC) in cell culture [29-31]. This assay is based upon the principle that only CSC can survive and grow without attachment in the absence of serum. As shown in Figure 2A, ShEC-PC3 cells formed a significantly ($p \leq 0.001$) higher number and bigger sized prostatespheres compared to Sh-PC3 cells. These results suggested that E-cadherin knock-down increases the stemness in PC3 cells.

We also analyzed the disintegration or differentiation of prostatespheres in the presence of attachment with or without the addition of serum. Prostatespheres were pipetted and re-plated on normal attachment culture plates with or without 10% FBS. In the absence of serum, both ShEC-PC3 and Sh-PC3 prostatespheres attached to the bottom of the plate but their disintegration was hardly visible even after 5 days. However, in the presence of serum both




Sh-PC3 and ShEC-PC3 cells disintegrated into bulk of growing cells; though, in general, ShEC-PC3 prostaspheres generated a bigger mass of growing bulk cells compared to Sh-PC3 prostaspheres (Figure 2B).

E-cadherin knock-down increases the expression of stemness, EMT, and bone metastasis biomarkers in human PCA PC3 cells both *in vitro* and *in vivo*

Next, we analyzed the effect of E-cadherin knock down on stemness and mesenchymal biomarkers in human PCA PC3 cells. Western blot analysis showed that E-cadherin

knock-down resulted in increased expression of CD44 and cleaved Notch1 in ShEC-PC3 cells (Figure 3A), which are well known biomarkers for stemness [32-34]. E-cadherin knock-down also increased Egr-1 expression (Figure 3A), which is a regulator of CD44 promoter activity [35]. Furthermore, E-cadherin knock-down resulted in a strong increase in EMT biomarkers, the intermediate filament protein Vimentin and Integrin β 3 expression (Figure 3A). However, E-cadherin knock-down resulted in only a slight or no significant increase in the expression of other cadherins namely N-cadherin and OB-cadherin (Figure 3A).



Besides, we have earlier reported a strong increase in the levels of phosphorylated pSrc-tyr416 following E-cadherin knock-down in PC3 cells [36], a kinase associated with increased PCA invasiveness and bone metastasis [37]. E-cadherin knock-down also increased the expression of several other proteins that are important in bone metastasis. As shown in Figure 3B, ShEC-PC3 cells showed higher expression of CXCR4, which is known to play an important role in the migration of PCA cells towards the chemotactic signal (SDF1 α) secreted by bone endothelial cells [8,38]. We also observed increased expression of uPA, RANKL and RunX2, which are considered important for initiating/promoting osteoclastogenesis in bone by PCA cells (Figure 3B) [7,8]. Next, we examined the expression of the above mentioned biomarkers in ShEC-PC3 and Sh-PC3 tissues from the xenograft experiment (Figure 1C). As shown in Figure 4, ShEC-PC3 xenograft tissues showed low E-cadherin level but exhibited significantly higher expression of CD44, Notch1, pSrc-tyr416, β -catenin, CXCR4 and RANKL compared to Sh-PC3 xenograft tissues.

E-cadherin knock-down increases SNAI1 expression in human PCA PC3 cells both *in vitro* and *in vivo*

Next, we examined the expression of several transcriptional factors (SNAI1, β -catenin, and NF- κ B) in Sh-PC3 and ShEC-PC3 cells. We observed a strong increase in the

expression of SNAI1 in both cytoplasmic and nuclear fractions of ShEC-PC3 cells compared to Sh-PC3 cells (Figure 5A). However, we observed only a modest increase in nuclear β -catenin and a slight increase in nuclear NF- κ B subunit p65 expression without significant changes in the cytoplasmic β -catenin and p65 expression between ShEC-PC3 and Sh-PC3 cells (Figure 5A). Importantly, we also observed a strong increase in SNAI1 expression in the prostaspheres formed by ShEC-PC3 cells compared to Sh-PC3 cells (Figure 5B). Furthermore, SNAI1 expression was also increased in ShEC-PC3 xenograft tissues both in terms of increase in the overall immunoreactivity score as well as the percentage of SNAI1-positive cells (Figure 5C).

SNAI1 is critical for the stemness, clonogenicity and invasiveness of ShEC-PC3 cells

Since we observed a strong increase in SNAI1 expression following E-cadherin knock-down, we next examined whether the increase in SNAI1 controls the stemness, clonogenicity and invasiveness of ShEC-PC3 cells. Accordingly, we knocked-down SNAI1 expression in ShEC-PC3 cells using SNAI1 specific siRNA and performed prostasphere, clonogenic and invasion assays. As shown in Figure 6A-6C, SNAI1 knock-down strongly decreased the number as well as size of prostaspheres and clones (≥ 50 cells) ($p \leq 0.001$). SNAI1 knock-down also compromised the invasiveness of ShEC-PC3 cells ($p \leq 0.001$). Furthermore, SNAI1 knock-down resulted in decreased pSrc-tyr416, Src and CD44 levels, suggesting a role for SNAI1 in regulating their expression. These results confirmed the central role of SNAI1 in controlling stemness, clonogenicity, and invasiveness in ShEC-PC3 cells.

Low E-cadherin is associated with high SNAI1 and prostasphere formation

Next, we employed 4 cell lines (RWPE-1, WPE1-NA22, WPE1-NB14 and DU-145) and compared their E-cadherin and SNAI1 expression as well as capability to form prostaspheres. RWPE-1 is a non-tumorigenic HPV18 immortalized cell line derived from peripheral zone of an adult human prostate [39]. WPE1-NA22 and WPE1-NB14 were derived from RWPE-1 following 50 and 100 μ g/ml MNU (N-methyl-N-nitrosourea) exposure, respectively [39]. These cell lines have been well characterized [39], and WPE1-NB14 cells are considered more aggressive than WPE1-NA22 cells in terms of their proliferation, invasiveness and xenograft formation *in vivo* [39]. DU-145 is an androgen-independent human PCA cell line derived from brain metastasis. Together, these cell lines represent various stage of PCA development i.e. from normal to advanced metastatic stage. Immunoblot analysis showed low E-cadherin expression in the membrane fraction of DU-145 and WPE1-NB14 cells compared with WPE1-NA22 and RWPE-1 cells (Figure 7A). Relatively low E-cadherin was




Figure 4 (See legend on next page.)

(See figure on previous page.)

Figure 4 Expression of stemness, EMT, and bone metastasis biomarkers in Sh-PC3 and ShEC-PC3 xenograft tissues. Sh-PC3 and ShEC-PC3 xenograft tissues were analyzed for the expression of E-cadherin, CD44, Notch1, pSrc-tyr416, β -catenin, CXCR4 and RANKL by IHC as detailed in the methods. Immunoreactivity was analyzed in 5 random areas for each tumor tissue and was scored as 0+ (no staining), 1+ (weak staining), 2+ (moderate staining), 3+ (strong staining), 4+ (very strong staining). IHC scores (as mean \pm SEM) are shown as bar diagram of 5–10 samples.

observed in cytoplasmic fraction of all the cell lines tested with least expression in DU-145 cells (Figure 7A). On the contrary, nuclear SNAI1 expression was highest in DU-145 cells followed by WPE1-NB14, WPE1-NA22 and RWPE-1 cells (Figure 7A). Immunoblotting results

for E-cadherin and SNAI1 expression in these 4 cell lines were further confirmed by confocal microscopy (Figure 7B). Immunofluorescence analysis also showed that RWPE-1 cells have polygonal morphology with intact cell-cell contact that was progressively lost in WPE1-NA22,





Figure 5 Effect of E-cadherin knock-down on the expression of SNAI1 and other transcriptional factors. (A) Sh-PC3 and ShEC-PC3 cells were collected at similar confluency and nuclear/cytoplasmic fractions were prepared and analyzed for SNAI1, β -catenin, and p65 expression by Western blotting. Tubulin and histone H1 were used as loading control for cytoplasmic and nuclear fractions respectively. (B) Sh-PC3 and ShEC-PC3 prostaspheres were collected following centrifugation and cell lysates were prepared and analyzed for SNAI1 expression by Western blotting. (C) Sh-PC3 and ShEC-PC3 xenograft tissues were analyzed for the expression of SNAI1 by IHC. Immunoreactivity score was analyzed in 5 random areas for each tumor tissue and was scored as 0+ (no staining), 1+ (weak staining), 2+ (moderate staining), 3+ (strong staining), 4+ (very strong staining). Percentage of SNAI1 positive cells was calculated by counting the number of positive stained cells (brown stained) and the total number of cells at five arbitrarily selected fields from each tumor at 400x magnification. The data shown in the bar diagrams is the mean \pm SEM of 7–10 samples. *, $p \leq 0.001$.



WPE1-NB14 and DU-145 cells together with a decrease in E-cadherin and an increase in SNAI1 expression (Figure 7B). Next, we compared the prostasphere formation in these 4 cell lines. As shown in Figure 7C, RWPE-1 and WPE1-NA22 cells did not form prostaspheres or formed relatively smaller sized prostaspheres, while WPE1-NB14 and DU-145 cells formed larger number and bigger sized prostaspheres. Overall, DU-145 cells (with lowest E-cadherin and highest SNAI1 expression) formed highest number and biggest sized prostaspheres among all the four cell lines studied here (Figure 7C).

Discussion

Lately, targeted therapies are being exploited to develop personalized medicines based upon the specific mutations and molecular alterations in cancer cells. Accordingly, the identification and functional characterization of important early molecular alterations, which are involved in the growth and progression of prostate cancer (PCA), remain vital towards devising novel targeted preventive and therapeutic strategies. In PCA patients, the main cause of death

is the metastatic spread of the disease; however, it remains extremely difficult to predict indolent versus aggressive tumor when diagnosed at an early stage. Now, EMT has been suggested to be required by stationary cancer cells to acquire phenotypic and functional characteristics for metastasis. Therefore, EMT biomarkers have been extensively examined to predict disease outcome [20-23,26]. In this regard, E-cadherin loss or reduced expression at the membrane of neoplastic cells has often been associated with worsening histological grade and clinical stage along with poor prognosis in a variety of cancers including prostate, gastric, and breast [18,19,23,40,41]. However, heterogeneity in E-cadherin expression has been observed in PCA metastatic tissues with few studies reporting reduced E-cadherin expression while others reporting normal or higher E-cadherin expression in metastatic tissues compared to primary tumor tissues [21,22,42-45]. Putzke *et al.* even reported difference in the E-cadherin expression dependent upon the metastatic organ site with significantly higher E-cadherin expression observed in bone metastatic tissues compared to soft tissue metastases




Figure 7 (See legend on next page.)

(See figure on previous page.)

Figure 7 Low E-cadherin is associated with high SNAI1 and prostasphere formation. (A-B) E-cadherin and SNAI1 expression was analyzed in RWPE-1, WPE1-NA22, WPE1-NB14, and DU-145 cells via immunoblotting and confocal microscopy methods. Representative confocal pictures are shown (at 1500x) where Alexa Fluor 555-red is for E-cadherin, Alexa Fluor 488-green is for SNAI1, while DAPI-blue stains nuclei. (C) RWPE-1, WPE1-NA22, WPE1-NB14, and DU-145 cells were plated on 6 well Corning ultra-low attachment plates in DMEM/F-12(Ham) media containing supplements B27 and N2. Prostasphere formation was measured after 8 days. Representative prostasphere pictures are shown at 100x. Data shown is mean \pm SEM of 3 samples. * $p \leq 0.001$ (compared to RWPE-1 prostasphere number).

[41]. The expression of another EMT regulator i.e. SNAI1 has also been correlated with an increased risk of tumor relapse and poor survival in breast cancer patients, and with the progression of colorectal cancer [23,46,47]. Recently, Whiteland *et al.* [23], using 215 archival PCA patient tissue samples analyzed the expression and sub-cellular localization of several EMT biomarkers to correlate them with disease outcome. This study revealed that loss of E-cadherin expression at the cellular membrane of PCA cells is significantly associated with increasing Gleason score and clinical stage, and a poor survival. Furthermore, nuclear SNAI1 expression was significantly increased in PCA tissue and was strongly associated with increasing Gleason score and clinical stage but did not demonstrate a significant association with PSA (prostate specific antigen) recurrence or patient survival. Therefore, E-cadherin and SNAI1 are important in the clinical progression of the disease; and in the present study, we demonstrate the role of E-cadherin and SNAI1 in conferring several aggressive characteristics to PCA cells such as higher proliferation rate, clonogenicity, stemness and increased expression of biomarkers for stemness, EMT, and metastasis.

There have been several studies suggesting that EMT not only enhances the motility and invasiveness of cancer cells, but also provide several additional aggressive features such as stemness, therapeutic and anoikis resistance etc. Gupta *et al.* [13] have shown that E-cadherin down-regulation not only induces EMT but also enhances the CSC population in breast cancer cells. In fact, a greater degree of overlapping has been observed in the CSC population as well as invasive or metastatic cells. Balic *et al.* reported that most of the early disseminated cancer cells detected in the bone marrow of breast cancer patients have a putative CSC phenotype [48]. In another study, Aktas *et al.* showed that a major proportion of circulating tumor cells in the blood of breast cancer patients has stem cell characteristics [49]. One explanation put forward to describe high-stemness in metastatic cancer cells is that 'stationary CSC' could undergo EMT and give rise to 'metastatic CSC' [50-52]. Another line of experimental evidence suggests that EMT induction in differentiated neoplastic epithelial cells (non-CSC population) not only enhances invasiveness but also their stemness [13,14,51,53,54]. In any case, increased stemness might provide the necessary plasticity to cancer cells required to adapt to varying microenvironments during the arduous metastatic journey

and colonization at distant organ sites. Results from the present study also support the argument that 'EMT enhances stemness' as E-cadherin knock-down significantly enhanced the clone and prostasphere formation by PC3 cells. However, Celia-Terrassa *et al.* have reported that PC3-derived clonal populations enriched for epithelial phenotype exhibit a stronger expression of self-renewal/pluripotency gene networks and more aggressive attributes [55]. Furthermore, the suppression of epithelial program inhibited the self-renewal/pluripotency gene network of tumor cells, their capacity to grow under attachment-independent conditions, and their tumorigenic and metastatic potentials [55]. This study also suggested the coexistence of heterogeneous populations with epithelial or mesenchymal phenotype interacting and co-operating to impact on the tumor's potency for local invasiveness and distant metastasis. Together, these studies highlight the plasticity in PCA cells where epithelial, mesenchymal, and intermediate or a mix of these states could impart contextual advantages dependent upon cancer stage and/or tumor microenvironment.

SNAI1 is a member of the zinc-finger transcription factor family and is known to repress E-cadherin expression [56]. SNAI1 is located on chromosome 20q13 that exhibits gene amplification in tumor samples from metastatic PCA [57]. Increased SNAI1 expression is considered an early event in the progress of prostate carcinogenesis but is limited to cells with invasive properties [26]. SNAI1 is also reported to enhance RANKL expression, osteoclastogenesis and bone colonization [58]. Furthermore, SNAI1 regulates CSC activity and tumorigenicity in breast and colorectal carcinoma cells [14,28]; and CRC patients with abundant SNAI1 expression exhibit high metastasis [28]. Baygi *et al.* reported that SNAI1 knock-down significantly reduced the viability of human PCA cells and prevented their re-attachment potential through modulating the expression of Integrins [24]. This study also suggested that SNAI1 primarily acts as a survival factor and inhibitor of cellular senescence. SNAI1 overexpression in ARCaP PCA cells induced EMT through ROS (reactive oxygen species) generation, increase in the expression of inflammatory chemokine CCL5 and ERK activation [59]; and SNAI1 knock-down in C4-2 and ARCaP cells overexpressing SNAI1 significantly compromised their migration potential [60]. Neal *et al.* have reported that higher SNAI1 expression could promote migration and invasion in PCA cells

through negatively regulating the expression of protease inhibitor Maspin [61]. SNAIL1 has also been reported to increase the expression of mesenchymal markers Vimentin and Fibronectin as well as other proteins involved in cancer invasion such as metalloproteinases 2 and 9, and various transcription factors such as ZEB-1 and LEF-1 [62,63]. SNAIL1 expression is inversely correlated with RKIP (Raf kinase inhibitor protein), a metastatic suppressor protein that inhibits cell survival, proliferation and invasiveness through targeting Raf-1/MEK/ERK and NF- κ B signaling pathways [63,64]. In the present study, we observed that knock-down of E-cadherin expression in PC3 cells resulted in a strong increase in SNAIL1 expression both in cell culture (cells and prostatespheres) as well as xenograft tissues; and that SNAIL1 inhibition reduced the stemness, clonogenicity and invasiveness of ShEC-PC3 cells. It is possible that SNAIL1 inhibition reduces the survival of ShEC-PC3 cells potentially by inducing senescence and/or apoptosis involving down-regulation of Integrins, Vimentin or other EMT regulators, decrease in ROS level, and increase in Maspin and/or RKIP as reported in above studies. Our results also suggested that SNAIL1 inhibition could reduce the stemness of ShEC-PC3 cells through a decrease in CD44 expression (as shown in Figure 6D). Also, SNAIL1 knock-down in ShEC-PC3 cells could reduce the invasiveness through inhibiting Src phosphorylation (Figure 6D). Therefore, there could be several molecular mechanisms possible for the inhibitory effect of SNAIL1 knock-down on the stemness and invasiveness of ShEC-PC3 cells, and these need to be investigated further in future.

It is now well established that SNAIL1 transcriptionally down-regulates E-cadherin expression; however, here we report an interesting finding that SNAIL1 expression is increased following E-cadherin knock-down in PC3 cells. Therefore, the loss of E-cadherin and SNAIL1 up-regulation could be inter-related during prostate carcinogenesis, where SNAIL1 increase could repress E-cadherin expression, and vice versa. Earlier studies have shown that GSK-3 β (glycogen synthase kinase-3 beta) phosphorylates SNAIL1 and promotes its export from the nucleus and subsequent degradation by the proteasome in the cytosol [19,65]. Conversely, PAK1 (p21-activated kinase) could phosphorylate SNAIL1 to promote its nuclear localization and activity as a transcriptional factor [19,66]. Du *et al.* reported that protein kinase D1 (PKD1) could also phosphorylate SNAIL1 at Ser11, triggering its nuclear export via 14-3-3 σ binding [19]. Wu *et al.* have shown that NF- κ B also plays an important role in the stabilization of SNAIL1 [19,67]. One possibility for the observed increase in SNAIL1 expression with E-cadherin knock-down could be increased nuclear β -catenin which could enhance SNAIL1 expression. Similarly, there was a slight increase in nuclear p65 expression with E-cadherin knock-down, which could also enhance SNAIL1 expression. Also, E-cadherin knock-down

could modify the phosphorylation status of SNAIL1 favoring its nuclear localization and stabilization possibly through a decrease in GSK-3 β and/or PKD1 or an increase in PAK1 and/or NF- κ B activity. Further studies are warranted to clearly define the molecular mechanisms through which E-cadherin loss results in higher SNAIL1 expression.

Together, the existing literature as well as results from the present study suggest that it is feasible to prevent metastasis in PCA patients with localized disease through re-activating/increasing E-cadherin expression or through targeting SNAIL1 expression in PCA cells by using existing or novel cancer preventive agents [68-70]. For example, earlier we have reported that in TRAMP (transgenic adenocarcinoma of the mouse prostate) mice E-cadherin expression is lost while SNAIL1 expression is increased with disease progression from PIN to poorly differentiated adenocarcinoma stages [70]; and the administration of the cancer chemopreventive agent Silibinin, a natural flavonoid from Milk thistle extract, strongly enhanced E-cadherin expression while it decreased SNAIL1 expression and prevented PCA metastasis to distant organs [70]. Recently, Harney *et al.* developed a novel strategy to target SNAIL1 expression in cancer cells [71]. They conjugated Co(III)Schiff base complexes with specific oligonucleotide i.e. Co(III)-Ebox selectively targeting the E-box-binding zinc finger family transcriptional factors resulting in enhanced E-cadherin promoter activity in MCF7 cells [71]. But it should be cautioned that SNAIL1 plays an important role during embryonic development and is also considered an important stem cell regulator, therefore SNAIL1 inhibitors should be specifically targeted towards cancer cells. Also, SNAIL1 inhibition could possibly cause the re-expression of E-cadherin as well as other epithelial markers in metastatic tissues, where higher E-cadherin or epithelial characteristics could favor better survival and proliferation [41,55]. This clearly reflects the challenge of understanding and targeting the epithelial plasticity in PCA, as E-cadherin promotion and SNAIL1 downregulation could prevent growth and invasiveness in primary tumors; however, could potentially enhance growth at certain metastatic sites.

Conclusions

Overall, results from the present study suggest that the EMT regulators- E-cadherin and SNAIL1 could be used for disease prognosis as well as suitably targeted to prevent PCA metastatic progression.

Methods

Cells culture and reagents

Human prostate carcinoma PC3, RWPE-1, WPE1-NA22, WPE1-NB14 and DU-145 cells were obtained from American Type Culture Collection (Manassas, VA). Sh-PC3 and ShEC-PC3 cells were cultured in RPMI1640 medium

supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 U/ml penicillin G, 100 µg/ml streptomycin sulfate and puromycin at 37°C in a humidified 5% CO₂ incubator. RWPE-1, WPE1-NA22, and WPE1-NB14 cells were cultured in keratinocyte serum-free medium containing 50 µg/ml bovine pituitary extract and 5 ng/ml epidermal growth factor. DU-145 cells were cultured in RPMI1640 medium supplemented with 10% heat inactivated FBS, 100 U/ml penicillin G and 100 µg/ml streptomycin sulfate. Media and other cell culture materials as well as fluorescently conjugated anti-mouse and anti-rabbit IgG antibodies were from Invitrogen Corporation (Gaithersburg, MD). Antibodies for β-catenin, Vimentin, Egr-1 (early growth response-1), CXCR4, uPA (Urokinase plasminogen activator), RANKL (receptor activator of nuclear factor kappa-B ligand), p65, RunX2, Histone H1 and E-cadherin shRNA plasmid were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies for E-cadherin, CD44, Integrin β3, SNAI1, cleaved Notch1, pSrc-tyr416, total Src, and anti-rabbit peroxidase-conjugated secondary antibody were obtained from Cell Signaling (Beverly, MA). SNAI1, N-cadherin, OB-cadherin and TATA-binding protein (TBP) antibodies were from Abcam (Cambridge, MA). Puromycin, DAPI (4',6-diamidino-2-phenylindole), and β-actin antibody were from Sigma-Aldrich (St Louis, MO). ECL detection system and anti-mouse HRP-conjugated secondary antibody were from GE Healthcare (Buckinghamshire, UK). On-Target plus smart pool SNAI1 siRNA was purchased from Thermo Scientific (Waltham, MA) and HiPerfect transfection reagent was from Qiagen (Valencia, CA). Antibody for α-tubulin was from Lab Vision Corporation (Fremont, CA). All other reagents were obtained in their commercially available highest purity grade.

Transfection

PC3 cells with stable knock-down of E-cadherin (ShEC-PC3 cells) and respective control cells (Sh-PC3 cells) were generated as published earlier [36]. For SNAI1 knock-down, ShEC-PC3 cells (~5×10⁵) were plated in 60 mm dishes for 24 hrs. SNAI1 siRNA and transfection reagents were mixed in 100 µl serum free media and added drop-wise over ShEC-PC3 cells. Serum containing media was added 1 hr after transfection. Cells were collected after 48 hrs and knock-down was confirmed by Western blotting. In other studies, cells were also collected and analyzed in clonogenic, prostasphere and invasion assays.

MTT assay

Sh-PC3 and ShEC-PC3 Cells were plated at a density of 1000 cells/well in 96-well plate under standard culture conditions. At the end of indicated time-point, fresh media containing 20 µl of MTT (5 mg/ml stock) was added, and incubated for another 4 h in a CO₂ incubator. At the end,

media was removed and 200 µl of DMSO was added to each well. Color intensity was measured by taking absorbance at 540 nm.

Clonogenic assay

Sh-PC3 and ShEC-PC3 cells (~ 1×10³ per well) were plated in 6-well plates. Fresh media was added every 48 h. At the end of the 7th day, cells were washed twice with ice cold PBS, fixed with a mixture of methanol and glacial acetic acid (3:1) for 10 minutes and then stained with 1% crystal violet in methanol for 15 minutes followed by washing with deionized water. Colonies with more than 50 cells were scored and counted under the microscope. Photomicrographs were taken using Canon Power Shot digital camera.

Matrigel invasion assay

Invasion assay was performed using matrigel invasion chambers from BD Biosciences as per vendor's protocol. Briefly, the bottom chambers were filled with RPMI1640 media with 10% FBS and the top chambers (inserts) were seeded with 50,000 cells (mock or SNAI1 siRNA transfected) per well in RPMI1640 media (with 0.5% FBS). Top chambers have a thin layer of matrigel, and PCA cells invaded through the matrigel layer and 8 micron membrane pores. After 22 h of incubation under standard culture conditions, cells on the top matrigel surface (non-invasive cells) were scraped with a cotton swab and the cells spreading on the bottom sides of the membrane (invasive cells) were fixed, stained, and mounted. Images were captured using Cannon Power Shot A640 camera on Zeiss inverted microscope and total number of invasive cells was counted and percentage of cell invasion was calculated.

Prostasphere assay

Sh-PC3, ShEC-PC3, RWPE-1, WPE1-NA22, WPE1-NB14 and DU-145 cells (1000, 2500, 5000, or 10000 cells) were plated in 6 well Corning ultra-low attachment plates in DMEM/F-12(Ham) media containing supplements B27 and N2 (from Invitrogen). Cell culture was monitored daily to assess that sphere originated from single cell; however cells or spheres aggregation cannot be completely ruled out. In each case, number of prostaspheres (with average diameter more than 75 µm) formed after 5–8 days was counted under a microscope. Prostasphere images were captured using Cannon Power Shot A640 camera on Zeiss inverted microscope.

Immunoblotting

Total or nuclear/cytoplasmic lysates were prepared following published protocol [72,73] and sub-cellular fractionations were prepared as per vendor's protocol (ThermoFisher Scientific, Rockford, IL). Approximately, 50–70 µg of protein

lysate per sample was denatured in 2x sample buffer and subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) on 6 or 12% Tris–glycine gel (as required based upon the protein molecular weight). The separated proteins were transferred on to nitrocellulose membrane followed by blocking with 5% non-fat milk powder (w/v) in Tris-buffered saline (10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 0.1% Tween 20) for 1 h at room temperature. Membranes were probed for the protein levels of desired molecules using specific primary antibodies followed by the appropriate peroxidase-conjugated secondary antibody and visualized by ECL detection system. To ensure equal protein loading, each membrane was stripped and re-probed with appropriate loading control. The autoradiograms/bands were scanned with Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA). In each case, blots were subjected to multiple exposures on the film to make sure that the band density is in the linear range.

Xenograft study and Immunohistochemistry (IHC)

Athymic (*nu/nu*) male nude mice were housed at the University of Colorado Denver (UCD) animal care facility. Protocols were approved by UCD Institutional Animal Care and Use Committee. Approximately, 1 million Sh-PC3 or ShEC-PC3 cells were suspended in 0.05 ml of serum-free medium (RPMI1640), mixed with 0.05 ml of matrigel and were s.c. injected in each flank of male athymic nude mouse (NCI-Frederick, Bethesda, MD) ($n = 5$ with total 10 xenografts for each group) to initiate tumor growth. Once the tumor xenograft started growing, their sizes were measured (every 4th day) in two dimensions using a digital caliper. The tumor volume was calculated by the formula: $0.5236 L_1(L_2)^2$, where L_1 is the long diameter and L_2 is short diameter. At the end, each tumor was carefully dissected and processed for IHC following published methods [74]. Briefly, sections were incubated with desired primary antibody followed by incubation with a specific biotinylated secondary antibody, followed by conjugated HRP streptavidin, DAB working solution, and finally counterstained with hematoxylin. Stained tumor sections were analyzed by Zeiss AxioScope 2 microscope and images were captured by the AxioCam MrC5 camera at 400x magnifications.

Confocal imaging

RWPE-1, WPE1-NA22, WPE1-NB14 and DU-145 cells were grown on cover slips and incubated in media for 24 hrs. Cells were then fixed in 3.7% formaldehyde, washed with PBS, permeabilized with 0.2% Triton X-100 overnight at 4°C along with primary antibodies for E-cadherin and SNAI1. Cells were then washed with PBS and incubated with secondary antibodies and DAPI for 60 min. Cell images were captured at 1500x magnification

on a Nikon inverted confocal microscope using 561/488/405 nm laser wavelengths to detect E-cadherin (Red), SNAI1 (Green) and DAPI (Blue) emissions, respectively.

Statistical analysis

Statistical analysis was performed using SigmaStat 2.03 software (Jandel Scientific, San Rafael, CA). Data was analyzed using one way ANOVA and a statistically significant difference was considered at $p < 0.05$.

Competing interests

The authors declare that they have no competing interests

Authors' contributions

GD contributed to the conception and design of the study, coordinated the research, performed the xenograft, Western blotting, prostasphere and knock-down experiments, and wrote the manuscript. AKJ performed the IHC. AR and HT performed the confocal studies, Western blotting for several proteins and proof read the manuscript. KCV and SCG carried out the MTT and clonogenic assays. CA contributed in the design of several experiments, Western blotting and proof read the manuscript. RA conceived the study, elaborated its design, coordinated the research, and critically revised the manuscript. All the authors have read and approved the final manuscript.

Acknowledgements

This work was supported by NCI RO1 grant CA102514 (to RA) and Institutional Research Grant 57-001-53 from the American Cancer Society (to GD). Authors also acknowledge the CCSG P30CA046934 grant for supporting the UCD Shared Resources used in this study.

Author details

¹Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, USA. ²University of Colorado Cancer Center, University of Colorado Denver, Aurora, Colorado, USA. ³Department of Molecular Biology and Biotechnology, Tezpur University, Tezpur, India.

Received: 25 September 2013 Accepted: 21 February 2014

Published: 24 February 2014

References

1. Siegel R, Naishadham D, Jemal A: **Cancer statistics, 2013.** *CA Cancer J Clin* 2013, **63**:11–30.
2. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA: **Molecular biology of bone metastasis.** *Mol Cancer Ther* 2007, **6**:2609–2617.
3. Tantivejkul K, Kalikin LM, Pienta KJ: **Dynamic process of prostate cancer metastasis to bone.** *J Cell Biochem* 2004, **91**:706–717.
4. Hadaschik BA, Gleave ME: **Therapeutic options for hormone-refractory prostate cancer in 2007.** *Urol Oncol* 2007, **25**:413–419.
5. Ye XC, Choueiri M, Tu SM, Lin SH: **Biology and clinical management of prostate cancer bone metastasis.** *Front Biosci* 2007, **12**:3273–3286.
6. Saad F, Markus R, Goessl C: **Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.** *BJU Int* 2008, **101**:1071–1075.
7. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M: **Mechanisms of bone metastasis in prostate cancer: clinical implications.** *Best Pract Res Clin Endocrinol Metab* 2008, **22**:341–355.
8. Bujs JT, van der Pluijm G: **Osteotropic cancers: from primary tumor to bone.** *Cancer Lett* 2009, **273**:177–193.
9. Deep G, Agarwal R: **Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.** *Cancer Metastasis Rev* 2010, **29**:447–463.
10. Guarino M, Rubino B, Ballabio G: **The role of epithelial-mesenchymal transition in cancer pathology.** *Pathology* 2007, **39**:305–318.
11. Christiansen JJ, Rajasekaran AK: **Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.** *Cancer Res* 2006, **66**:8319–8326.
12. Drasin DJ, Robin TP, Ford HL: **Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity.** *Breast Cancer Res* 2011, **13**:226.

13. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES: **Identification of selective inhibitors of cancer stem cells by high-throughput screening.** *Cell* 2009, **138**:645–659.
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: **The epithelial-mesenchymal transition generates cells with properties of stem cells.** *Cell* 2008, **133**:704–715.
15. Polyak K, Weinberg RA: **Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.** *Nat Rev Cancer* 2009, **9**:265–273.
16. Baranwal S, Alahari SK: **Molecular mechanisms controlling E-cadherin expression in breast cancer.** *Biochem Biophys Res Commun* 2009, **384**:6–11.
17. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T, Li MC, Lin YH: **Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.** *Int J Urol* 2007, **14**:1034–1039.
18. Peinado H, Olmeda D, Cano A: **Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?** *Nat Rev Cancer* 2007, **7**:415–428.
19. Du C, Zhang C, Hassan S, Biswas MH, Balaji KC: **Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail.** *Cancer Res* 2010, **70**:7810–7819.
20. Umbas R, Isaacs WB, Bringer PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA: **Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.** *Cancer Res* 1994, **54**:3929–3933.
21. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaacs WB: **Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.** *Cancer Res* 1992, **52**:5104–5109.
22. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG: **Expression of E-cadherin in primary and metastatic prostate cancer.** *Am J Pathol* 1996, **148**:1375–1380.
23. Whiteland H, Spencer-Harty S, Thomas DH, Davies C, Morgan C, Kynaston H, Bose P, Fenn N, Lewis P, Bodger O, Jenkins S, Doak SH: **Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer.** *Exp Mol Pathol* 2013, **95**:220–226.
24. Emadi Baygi M, Soheil ZS, Schmitz I, Sameie S, Schulz WA: **Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines.** *Cell Biol Toxicol* 2010, **26**:553–567.
25. McKeithen D, Graham T, Chung LW, Odero-Marrah V: **Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells.** *Prostate* 2010, **70**:982–992.
26. Heeboll S, Borre M, Ottosen PD, Dyrskjot L, Orntoft TF, Topping N: **Snail1 is over-expressed in prostate cancer.** *APMIS* 2009, **117**:196–204.
27. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM: **ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.** *Cancer Cell* 2010, **17**:319–332.
28. Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH, Wang HW: **SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells.** *Gastroenterology* 2011, **141**:279–291. e271–275.
29. Hurt EM, Kawasaki BT, Klarman GJ, Thomas SB, Farrar WL: **CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.** *Br J Cancer* 2008, **98**:756–765.
30. Bisson I, Prowse DM: **WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics.** *Cell Res* 2009, **19**:683–697.
31. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG: **In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.** *Prostate* 2009, **69**:1683–1693.
32. Klarman GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL: **Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature.** *Clin Exp Metastasis* 2009, **26**:433–446.
33. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, Kim YS, Farrar WL: **Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach.** *Prostate* 2009, **69**:827–837.
34. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG: **Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.** *Oncogene* 2006, **25**:1696–1708.
35. Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA: **Silibinin suppresses CD44 expression in prostate cancer cells.** *Am J Transl Res* 2009, **1**:80–86.
36. Deep G, Gangar SC, Agarwal C, Agarwal R: **Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells.** *Cancer Prev Res (Phila)* 2011, **4**:1222–1232.
37. Saad F, Lipton A: **SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.** *Cancer Treat Rev* 2010, **36**:177–184.
38. Eaton CL, Colomel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalmann G: **Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.** *Prostate* 2010, **70**:875–882.
39. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-Calaca W, Williams DE: **Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.** *Prostate* 2001, **47**:1–13.
40. van Roy F, Berx G: **The cell-cell adhesion molecule E-cadherin.** *Cell Mol Life Sci* 2008, **65**:3756–3788.
41. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS: **Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.** *Am J Pathol* 2011, **179**:400–410.
42. Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen S, Jones LW, Imam SA: **Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.** *Prostate* 2008, **68**:78–84.
43. Pontes J Jr, Srougi M, Borra PM, Dall'Oglio MF, Ribeiro-Filho LA, Leite KR: **E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer.** *Appl Immunohistochem Mol Morphol* 2010, **18**:179–184.
44. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML: **E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.** *Hum Pathol* 2001, **32**:690–697.
45. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI: **E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.** *Urology* 1999, **53**:707–713.
46. Fan XJ, Wan XB, Yang ZL, Fu XH, Huang Y, Chen DK, Song SX, Liu Q, Xiao HY, Wang L, Wang JP: **Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer.** *Hum Pathol* 2013, **44**:173–180.
47. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA: **The transcriptional repressor Snail promotes mammary tumor recurrence.** *Cancer Cell* 2005, **8**:197–209.
48. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ: **Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.** *Clin Cancer Res* 2006, **12**:5615–5621.
49. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: **Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.** *Breast Cancer Res* 2009, **11**:R46.
50. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T: **Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression.** *Nat Rev Cancer* 2005, **5**:744–749.
51. Gupta PB, Chaffer CL, Weinberg RA: **Cancer stem cells: mirage or reality?** *Nat Med* 2009, **15**:1010–1012.
52. Li H, Tang DG: **Prostate cancer stem cells and their potential roles in metastasis.** *J Surg Oncol* 2011, **103**:558–562.
53. van der Pluijm G: **Epithelial plasticity, cancer stem cells and bone metastasis formation.** *Bone* 2011, **48**:37–43.
54. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A: **Generation of breast cancer stem cells through epithelial-mesenchymal transition.** *PLoS One* 2008, **3**:e2888.
55. Celia-Terrasa T, Meca-Cortes O, Mateo F, de Paz AM, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M, Lozano JJ, Estaras C, Ulloa C, Alvarez-Simon D, Mila J, Vilella R, Paciucci R, Martinez-Balbas M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernandez PL, Thomson TM: **Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells.** *J Clin Invest* 2012, **122**:1849–1868.

56. Foubert E, De Craene B, Bex G: **Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression.** *Breast Cancer Res* 2010, **12**:206.
57. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: **Delineation of prognostic biomarkers in prostate cancer.** *Nature* 2001, **412**:822–826.
58. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhou HE, Chung LW: **Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.** *Cell Res* 2008, **18**:858–870.
59. Barnett P, Arnold RS, Mezencev R, Chung LW, Zayzafoon M, Odero-Marah V: **Snail-mediated regulation of reactive oxygen species in ARCAp human prostate cancer cells.** *Biochem Biophys Res Commun* 2011, **404**:34–39.
60. Neal CL, McKeithen D, Odero-Marah VA: **Snail negatively regulates cell adhesion to extracellular matrix and integrin expression via the MAPK pathway in prostate cancer cells.** *Cell Adh Migr* 2011, **5**:249–257.
61. Neal CL, Henderson V, Smith BN, McKeithen D, Graham T, Vo BT, Odero-Marah VA: **Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells.** *BMC Cancer* 2012, **12**:336.
62. Smith BN, Odero-Marah VA: **The role of Snail in prostate cancer.** *Cell Adh Migr* 2012, **6**:433–441.
63. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B: **Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.** *Oncogene* 2009, **28**:3573–3585.
64. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC: **Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.** *Oncogene* 2008, **27**:2243–2248.
65. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: **Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition.** *Nat Cell Biol* 2004, **6**:931–940.
66. Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R: **Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions.** *Cancer Res* 2005, **65**:3179–3184.
67. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP: **Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion.** *Cancer Cell* 2009, **15**:416–428.
68. Roy HK, Kunte DP, Koetsier JL, Hart J, Kim YL, Liu Y, Bissonnette M, Goldberg M, Backman V, Wali RK: **Chemoprevention of colon carcinogenesis by polyethylene glycol: suppression of epithelial proliferation via modulation of SNAIL/beta-catenin signaling.** *Mol Cancer Ther* 2006, **5**:2060–2069.
69. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, Mukhtar H: **Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.** *Cancer Res* 2004, **64**:3334–3343.
70. Raina K, Rajamanickam S, Singh RP, Deep G, Chittechath M, Agarwal R: **Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.** *Cancer Res* 2008, **68**:6822–6830.
71. Harney AS, Meade TJ, LaBonne C: **Targeted inactivation of Snail family EMT regulatory factors by a Co(III)-Ebox conjugate.** *PLoS One* 2012, **7**:e32318.
72. Zi X, Feyes DK, Agarwal R: **Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins.** *Clin Cancer Res* 1998, **4**:1055–1064.
73. Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R: **Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft.** *Mol Cancer Ther* 2009, **8**:2366–2374.
74. Singh RP, Deep G, Chittechath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R: **Effect of silibinin on the growth and progression of primary lung tumors in mice.** *J Natl Cancer Inst* 2006, **98**:846–855.

doi:10.1186/1476-4598-13-37

Cite this article as: Deep *et al.*: SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. *Molecular Cancer* 2014 **13**:37.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

